返回 
加入收藏
普罗布考联合瑞舒伐他汀治疗血管性痴呆的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 普罗布考联合瑞舒伐他汀治疗血管性痴呆的临床观察 |
| TITLE： | |
| 摘要： | 目的：探讨普罗布考联合瑞舒伐他汀治疗血管性痴呆（VD）的有效性和安全性。方法：采用回顾性研究法，收集2013年5月－2015年2月在我院神经内科治疗的88例VD患者的临床资料，按治疗方案不同分为观察组和对照组，各44例。两组患者均给予控制血压和血糖、抗凝等常规治疗；在此基础上，对照组患者于每日睡前口服瑞舒伐他汀钙片20 mg；观察组患者在对照组治疗基础上餐后口服普罗布考片0.5 g，bid。两组患者均连续治疗3个月。比较两组患者治疗前后简易智能状态检测量表（MMSE）和日常生活能力量表（ADL）评分，血清总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、C反应蛋白（CRP）、肿瘤坏死因子α（TNF-α）、白细胞介素6（IL-6）、IL-1β、超氧化物歧化酶（SOD）和丙二醛（MDA）水平，以及不良反应发生情况。 结果：治疗前，两组患者上述指标比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者MMSE和ADL评分、血清SOD水平均较治疗前明显升高，血清TC、TG、LDL-C、CRP、TNF-α、IL-6、IL-1β、MDA水平均较治疗前明显降低，差异均有统计学意义（P＜0.05）；且观察组患者上述指标均明显优于对照组，差异有统计学意义（P＜0.05）。两组患者HDL-C水平在治疗前后及组间比较，差异均无统计学意义（P＞0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。 结论：普罗布考联合瑞舒伐他汀较单用瑞舒伐他汀更能有效降低VD患者的血脂、血清炎症因子和氧化应激指标水平，提高患者的认知功能和生活质量，且安全性较好。 |
| ABSTRACT： | OBJECTIVE： To explore the effectiveness and safety of probucol combined with rosuvastatin in the treatment of vascular dementia （VD）. METHODS： In retrospective study， clinical information of 88 VD patients selected from neurology department of our hospital during May 2013-Feb. 2015 were divided into observation group and control group according to therapy plan， with 44 cases in each group. Both groups received conventional treatments such as controlling blood pressure and blood glucose， anticoagulation. Control group was additionally given Rosuvastatin calcium tablets orally 20 mg， at bedtime； observation group was additionally given Probucol tablet 0.5 g， bid， after meal， on the basis of control group. Both groups received treatment for consecutive 3 months. MMSE and ADL score were compared between 2 groups before and after treatment as well as the levels of TC， TG， LDL-C， HDL-C， CRP， TNF-α， IL-6， IL-1β， SOD and MDA. The occurrence of ADR was also observed. RESULTS： Before treatment， there was no statistical significance in above indexes between 2 groups （P＞0.05）. Compared to before treatment， MMSE and ALD score， serum SOD level of 2 groups were increased significantly， while serum levels of TC， TG， LDL-C， CRP， TNF-α， IL-6， IL-1β and MDA were decreased significantly after treatment， with statistical significance （P＜0.05）. Above indexes of observation group were significantly better than those of control group， with statistical significance （P＜0.05）. There was no statistical significance in HDL-C level between 2 groups before and after treatment （P＞0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）.CONCLUSIONS： Probucol combined with rosuvastatin is better than rosuvastatin alone in reducing blood lipid， serum inflammatory factors and oxidant stress indexes levels， improving cognitive function and quality of life with good safety. |
| 期刊： | 2017年第28卷第5期 |
| 作者： | 张潇，曾鼎华 |
| AUTHORS： | ZHANG Xiao，ZENG Dinghua |
| 关键字： | 普罗布考；瑞舒伐他汀；联合用药；血管性痴呆；血脂；炎症；氧化应激 |
| KEYWORDS： | Probucol； Rosuvastatin； Drug combination； Vascular dementia； Blood lipid； Inflammation； Oxidative stress |
| 阅读数： | 434 次 |
| 本月下载数： | 1 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
